PEPTONIC medical AB (FRA:28L) Ending Cash Position: €0.06 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PEPTONIC medical AB Ending Cash Position?

PEPTONIC medical AB FRA:28L Ending Cash Position is €0.06 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

PEPTONIC medical AB's Ending Cash Position for the quarter that ended in Mar. 2026 was €0.06 Mil.

PEPTONIC medical AB's quarterly Ending Cash Position declined from Sep. 2025 (€0.08 Mil) to Dec. 2025 (€0.02 Mil) but then increased from Dec. 2025 (€0.02 Mil) to Mar. 2026 (€0.06 Mil).

PEPTONIC medical AB's annual Ending Cash Position declined from Dec. 2023 (€1.35 Mil) to Dec. 2024 (€0.33 Mil) and declined from Dec. 2024 (€0.33 Mil) to Dec. 2025 (€0.02 Mil).

PEPTONIC medical AB Ending Cash Position Related Terms

PEPTONIC medical AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for PEPTONIC medical AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PEPTONIC medical AB Ending Cash Position Chart

PEPTONIC medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 0.32 1.35 0.33 0.02

PEPTONIC medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.52 0.08 0.02 0.06

PEPTONIC medical AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

PEPTONIC medical AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.343+-0.325
=0.02

PEPTONIC medical AB's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.017+0.041
=0.06

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.06 Mil mean?
PEPTONIC medical AB (FRA:28L) has a Ending Cash Position of €0.06 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PEPTONIC medical AB and its competitors.
Is PEPTONIC medical AB's Ending Cash Position too high?
PEPTONIC medical AB's current Ending Cash Position is €0.06 Mil.
How does PEPTONIC medical AB's Ending Cash Position compare to ZTS and UTHR?
PEPTONIC medical AB's Ending Cash Position of €0.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PEPTONIC medical AB and its competitors. PEPTONIC medical AB's current Ending Cash Position is €0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PEPTONIC medical AB stock overvalued right now?
PEPTONIC medical AB (FRA:28L) has a current Ending Cash Position of €0.06 Mil. The current Ending Cash Position is €0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For PEPTONIC medical AB (FRA:28L), the current Ending Cash Position is €0.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PEPTONIC medical AB Business Description

Other Exchanges PMED:Sweden
Address Gustavslundsvagen 143, Bromma, SWE, SE-167 51
PEPTONIC medical AB is a pharmaceutical company. It is engaged in developing oxytocin-based products for the treatment of menopausal symptoms, such as vaginal atrophy and vaginal dryness. Oxytocin is for medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. The company is based in Sweden.